AZTAAzenta, Inc.
Is the price fair?
A demanding price: priced for +29% a year vs −1% a year delivered and at the top of its own P/E range.
Priced for ~29% a year FCF growth. The price already bakes in strong, sustained growth.
Expensive vs its own history: P/E 59.9 vs a 28.5 median over 20 quarters (+110% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What AZTA's price assumes
Azenta, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.91× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.87%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +29%
Growth the price implies · The price pays for +29% free cash flow growth a year for a decade; revenue has grown −0.88% a year over the last three.
- Price / book
- 0.66
Price / book · today's price, fiscal year to Sep 30, 2025
Details›
- Price / booktoday's price, fiscal year to Sep 30, 2025
- 0.66
- EV / EBIToperating margin −29%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Sep 30, 2025
- 1.34
- Free cash flow, trailing twelve months
- $9.9M
- Market capitalisation
- $1.14B
- 3-year revenue growth
- −0.88%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #15 of 21 by RyuScore